United States - English - NLM (National Library of Medicine)

service drug dba petersen drug - oxygen (unii: s88tt14065) (oxygen - unii:s88tt14065) -

Australia - English - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - methotrexate sodium, quantity: 2.742 mg (equivalent: methotrexate, qty 2.5 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; lactose monohydrate; magnesium stearate - antineoplastic chemotherapy treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. chexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy (see warnings box and section 4.4) because of the high risk attending to its use, chexate is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations. rheumatoid arthritis chemotherapy (see warnings box and section 4.4) management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see section 4.4, and 4.5). steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australia - English - Department of Health (Therapeutic Goods Administration)

orion pharma (aus) pty limited - methotrexate sodium, quantity: 10.97 mg (equivalent: methotrexate, qty 10 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose - antineoplastic chemotherapy treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. chexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy (see warnings box and section 4.4) because of the high risk attending to its use, chexate is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations. rheumatoid arthritis chemotherapy (see warnings box and section 4.4) management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see section 4.4, and 4.5). steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

United States - English - NLM (National Library of Medicine)

peter thomas roth labs, llc - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - active ingredients.............................................................. purpose titanium dioxide i.93%................................................... sunscreen zinc oxide 19.24%..... ................................................... sunscreen uses helps prevent sunburn lf used as directed with other sun protection measures (see directions), decreases the risk of skin cancer and early skinaging caused by the sun

United States - English - NLM (National Library of Medicine)

peter thomas roth, llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - active ingredient purpose salicylic acid 2%.................................................................acne treatment uses - for the treatment and management of acne. - clears up acne blemishes and blackheads. - helps prevent new acne blemishes and blackheads.

Australia - English - Department of Health (Therapeutic Goods Administration)

avant innovations - 46148 - patient transfer system, manual - manual transfer aids for patients

Australia - English - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - 38000 - nylon suture, monofilament - the synthetic non-absorable surgical sutures cardionyl are composed of a polyamide monofilament, with or without pledget of different sizes. cardionyl sutures elicit a minimal acute inflammatory reaction in tissues, which is followed by gradual encapsulation of the suture by fibrous connective tissue. cardionyl sutures are intended for use in general soft tissue approximation and/or ligation, including use in cardiovascular and vascular surgery, in ophthalmic surgery and in neurological surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - 13906 - suture, polyester - the synthetic non-absorbable surgical sutures cardioxyl are composed of polyester braids, with or without pledget of different sizes. cardioxyl sutures elicit a minimal acute inflammatory reaction in tissues, which is followed by gradual encapsulation of the suture by fibrous connective tissue. cardioxyl sutures are not absorbed and there is no degradation or loss of strength. cardioxyl sutures are intended for use in general soft tissue approximation and/or ligation, including use in cardiovascular and vascular surgery, in ophthalmic surgery and in neurological surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - 13909 - suture, polypropylene monofilament - the synthetic non-absorbable surgical sutures corolene are composed of an isotactic polypropylene monofilament, with or without pledget of different sizes. corolene sutures elicit a minimal acute inflammatory reaction in tissues, which is followed by gradual encapsulation of the suture by fibrous connective tissue. corolene sutures are not absorbed and there is no degradation or loss of strength. the stainless steel needle is available in silver colour or extrablack colour. corolene sutures are intended for use in general soft tissue approximation and/or ligation, including use in cardiovascular and vascular surgery, in ophthalmic surgery and in neurological surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - 13909 - suture, polypropylene monofilament - the synthetic non-absorbable surgical sutures premio are composed of a pvdf monofilament, with or without pledget of different sizes. premio sutures elicit a minimal acute inflammatory reaction in tissues, which is followed by gradual encapsulation of the suture by fibrous connective tissue. premio sutures are not absorbed and there is no degradation or loss of strength. premio sutures are intended for use in general soft tissue approximation and/or ligation, including use in cardiovascular and vascular surgery, in ophthalmic surgery and in neurological surgery.